anti pms2 Search Results


msh6 za-0541 r antibody  (ZSGB Biotech)
90
ZSGB Biotech msh6 za-0541 r antibody
CWH22 and CLM22 organoids maintain histological and proliferative characteristics of the corresponding tumors. ( A ) H&E staining of the tumor organoids showing the resemblance of the organoids to the lumens and tubular structures of the primary tumor. IHC staining demonstrated consistent positive expression of CK20 and CDX2 in the organoids and corresponding tumors (scale bars, 100 μm). ( B ) IHC staining of CWH22 and CLM22 organoids demonstrating the consistent expression of p53, Ki67, MLH1, PMS2, MSH2, <t>MSH6,</t> and Villin, with the expression in CRC and CLM tissues . Scale bars, 100 μm. ( C ) Representative time course of CWH22 and CLM22 organoid growth for 14 days (scale bars, 500 μm) and local field amplification (scale bars, 200 μm). ( D ) Analysis of the proliferation rates of CWH22 and CLM22 organoids over time using 3D cell viability tests. ( E ) Bright-field images showing the morphology of CWH22 and CLM22 organoids at the 2nd, 5th, 10th, and 20th passages (P2, P5, P10, and P20, respectively; scale bars, 500 μm), and the expression of CK20 and Ki67 in representative differentiated organoids from CWH22 and CLM22 (scale bars, 50 μm).
Msh6 Za 0541 R Antibody, supplied by ZSGB Biotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/msh6 za-0541 r antibody/product/ZSGB Biotech
Average 90 stars, based on 1 article reviews
msh6 za-0541 r antibody - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
anti-mutlα (mlh1-his 6 -pms2) polyclonal antibodies  (Strategic BioSolutions Inc)
90
Strategic BioSolutions Inc anti-mutlα (mlh1-his 6 -pms2) polyclonal antibodies
CWH22 and CLM22 organoids maintain histological and proliferative characteristics of the corresponding tumors. ( A ) H&E staining of the tumor organoids showing the resemblance of the organoids to the lumens and tubular structures of the primary tumor. IHC staining demonstrated consistent positive expression of CK20 and CDX2 in the organoids and corresponding tumors (scale bars, 100 μm). ( B ) IHC staining of CWH22 and CLM22 organoids demonstrating the consistent expression of p53, Ki67, MLH1, PMS2, MSH2, <t>MSH6,</t> and Villin, with the expression in CRC and CLM tissues . Scale bars, 100 μm. ( C ) Representative time course of CWH22 and CLM22 organoid growth for 14 days (scale bars, 500 μm) and local field amplification (scale bars, 200 μm). ( D ) Analysis of the proliferation rates of CWH22 and CLM22 organoids over time using 3D cell viability tests. ( E ) Bright-field images showing the morphology of CWH22 and CLM22 organoids at the 2nd, 5th, 10th, and 20th passages (P2, P5, P10, and P20, respectively; scale bars, 500 μm), and the expression of CK20 and Ki67 in representative differentiated organoids from CWH22 and CLM22 (scale bars, 50 μm).
Anti Mutlα (Mlh1 His 6 Pms2) Polyclonal Antibodies, supplied by Strategic BioSolutions Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-mutlα (mlh1-his 6 -pms2) polyclonal antibodies/product/Strategic BioSolutions Inc
Average 90 stars, based on 1 article reviews
anti-mutlα (mlh1-his 6 -pms2) polyclonal antibodies - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
anti pms2 (ds-0161-b, mouse monoclonal primary antibody;concentrated dilution; 1:100)  (Diagnostic BioSystems)
90
Diagnostic BioSystems anti pms2 (ds-0161-b, mouse monoclonal primary antibody;concentrated dilution; 1:100)
CWH22 and CLM22 organoids maintain histological and proliferative characteristics of the corresponding tumors. ( A ) H&E staining of the tumor organoids showing the resemblance of the organoids to the lumens and tubular structures of the primary tumor. IHC staining demonstrated consistent positive expression of CK20 and CDX2 in the organoids and corresponding tumors (scale bars, 100 μm). ( B ) IHC staining of CWH22 and CLM22 organoids demonstrating the consistent expression of p53, Ki67, MLH1, PMS2, MSH2, <t>MSH6,</t> and Villin, with the expression in CRC and CLM tissues . Scale bars, 100 μm. ( C ) Representative time course of CWH22 and CLM22 organoid growth for 14 days (scale bars, 500 μm) and local field amplification (scale bars, 200 μm). ( D ) Analysis of the proliferation rates of CWH22 and CLM22 organoids over time using 3D cell viability tests. ( E ) Bright-field images showing the morphology of CWH22 and CLM22 organoids at the 2nd, 5th, 10th, and 20th passages (P2, P5, P10, and P20, respectively; scale bars, 500 μm), and the expression of CK20 and Ki67 in representative differentiated organoids from CWH22 and CLM22 (scale bars, 50 μm).
Anti Pms2 (Ds 0161 B, Mouse Monoclonal Primary Antibody;Concentrated Dilution; 1:100), supplied by Diagnostic BioSystems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti pms2 (ds-0161-b, mouse monoclonal primary antibody;concentrated dilution; 1:100)/product/Diagnostic BioSystems
Average 90 stars, based on 1 article reviews
anti pms2 (ds-0161-b, mouse monoclonal primary antibody;concentrated dilution; 1:100) - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
pms2 mouse anti-human monoclonal antibody (ep51  (Zhongshan Company)
90
Zhongshan Company pms2 mouse anti-human monoclonal antibody (ep51
CWH22 and CLM22 organoids maintain histological and proliferative characteristics of the corresponding tumors. ( A ) H&E staining of the tumor organoids showing the resemblance of the organoids to the lumens and tubular structures of the primary tumor. IHC staining demonstrated consistent positive expression of CK20 and CDX2 in the organoids and corresponding tumors (scale bars, 100 μm). ( B ) IHC staining of CWH22 and CLM22 organoids demonstrating the consistent expression of p53, Ki67, MLH1, PMS2, MSH2, <t>MSH6,</t> and Villin, with the expression in CRC and CLM tissues . Scale bars, 100 μm. ( C ) Representative time course of CWH22 and CLM22 organoid growth for 14 days (scale bars, 500 μm) and local field amplification (scale bars, 200 μm). ( D ) Analysis of the proliferation rates of CWH22 and CLM22 organoids over time using 3D cell viability tests. ( E ) Bright-field images showing the morphology of CWH22 and CLM22 organoids at the 2nd, 5th, 10th, and 20th passages (P2, P5, P10, and P20, respectively; scale bars, 500 μm), and the expression of CK20 and Ki67 in representative differentiated organoids from CWH22 and CLM22 (scale bars, 50 μm).
Pms2 Mouse Anti Human Monoclonal Antibody (Ep51, supplied by Zhongshan Company, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pms2 mouse anti-human monoclonal antibody (ep51/product/Zhongshan Company
Average 90 stars, based on 1 article reviews
pms2 mouse anti-human monoclonal antibody (ep51 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
anti-pms2  (ABclonal Biotechnology)
90
ABclonal Biotechnology anti-pms2
CWH22 and CLM22 organoids maintain histological and proliferative characteristics of the corresponding tumors. ( A ) H&E staining of the tumor organoids showing the resemblance of the organoids to the lumens and tubular structures of the primary tumor. IHC staining demonstrated consistent positive expression of CK20 and CDX2 in the organoids and corresponding tumors (scale bars, 100 μm). ( B ) IHC staining of CWH22 and CLM22 organoids demonstrating the consistent expression of p53, Ki67, MLH1, PMS2, MSH2, <t>MSH6,</t> and Villin, with the expression in CRC and CLM tissues . Scale bars, 100 μm. ( C ) Representative time course of CWH22 and CLM22 organoid growth for 14 days (scale bars, 500 μm) and local field amplification (scale bars, 200 μm). ( D ) Analysis of the proliferation rates of CWH22 and CLM22 organoids over time using 3D cell viability tests. ( E ) Bright-field images showing the morphology of CWH22 and CLM22 organoids at the 2nd, 5th, 10th, and 20th passages (P2, P5, P10, and P20, respectively; scale bars, 500 μm), and the expression of CK20 and Ki67 in representative differentiated organoids from CWH22 and CLM22 (scale bars, 50 μm).
Anti Pms2, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-pms2/product/ABclonal Biotechnology
Average 90 stars, based on 1 article reviews
anti-pms2 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
anti-pms2 mouse monoclonal antibody  (GeneTex)
90
GeneTex anti-pms2 mouse monoclonal antibody
CWH22 and CLM22 organoids maintain histological and proliferative characteristics of the corresponding tumors. ( A ) H&E staining of the tumor organoids showing the resemblance of the organoids to the lumens and tubular structures of the primary tumor. IHC staining demonstrated consistent positive expression of CK20 and CDX2 in the organoids and corresponding tumors (scale bars, 100 μm). ( B ) IHC staining of CWH22 and CLM22 organoids demonstrating the consistent expression of p53, Ki67, MLH1, PMS2, MSH2, <t>MSH6,</t> and Villin, with the expression in CRC and CLM tissues . Scale bars, 100 μm. ( C ) Representative time course of CWH22 and CLM22 organoid growth for 14 days (scale bars, 500 μm) and local field amplification (scale bars, 200 μm). ( D ) Analysis of the proliferation rates of CWH22 and CLM22 organoids over time using 3D cell viability tests. ( E ) Bright-field images showing the morphology of CWH22 and CLM22 organoids at the 2nd, 5th, 10th, and 20th passages (P2, P5, P10, and P20, respectively; scale bars, 500 μm), and the expression of CK20 and Ki67 in representative differentiated organoids from CWH22 and CLM22 (scale bars, 50 μm).
Anti Pms2 Mouse Monoclonal Antibody, supplied by GeneTex, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-pms2 mouse monoclonal antibody/product/GeneTex
Average 90 stars, based on 1 article reviews
anti-pms2 mouse monoclonal antibody - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
purified mouse anti pms2  (BD Biosciences)
N/A
   Buy from Supplier
rabbit anti- pms2 polyclonal antibody  (Cusabio)
N/A
Rabbit anti-Human PMS2 Polyclonal Antibody
   Buy from Supplier
rabbit anti human pms2 polyclonal affinity purified  (Innovative Research Inc)
N/A
Rabbit Anti Human PMS2 Polyclonal Affinity Purified (PBS with 0.05% sodium azide and 50% glycerol, pH7.4) (IHC,ELISA) from Innovative Research is a polyclonal antibody in a liquid format, buffered in PBS with 0.05% sodium azide
   Buy from Supplier
anti-pms2 rabbit monoclonal antibody  (Boster Bio)
N/A
Boster Bio Anti-PMS2 Rabbit Monoclonal Antibody catalog # M01028-1. Tested in WB, IHC, ICC/IF, IP, Flow Cytometry applications. This antibody reacts with Human.
   Buy from Supplier
rabbit anti-pms2 antibody  (RayBiotech)
N/A
PMS2 Polyclonal Antibody
   Buy from Supplier

Image Search Results


CWH22 and CLM22 organoids maintain histological and proliferative characteristics of the corresponding tumors. ( A ) H&E staining of the tumor organoids showing the resemblance of the organoids to the lumens and tubular structures of the primary tumor. IHC staining demonstrated consistent positive expression of CK20 and CDX2 in the organoids and corresponding tumors (scale bars, 100 μm). ( B ) IHC staining of CWH22 and CLM22 organoids demonstrating the consistent expression of p53, Ki67, MLH1, PMS2, MSH2, MSH6, and Villin, with the expression in CRC and CLM tissues . Scale bars, 100 μm. ( C ) Representative time course of CWH22 and CLM22 organoid growth for 14 days (scale bars, 500 μm) and local field amplification (scale bars, 200 μm). ( D ) Analysis of the proliferation rates of CWH22 and CLM22 organoids over time using 3D cell viability tests. ( E ) Bright-field images showing the morphology of CWH22 and CLM22 organoids at the 2nd, 5th, 10th, and 20th passages (P2, P5, P10, and P20, respectively; scale bars, 500 μm), and the expression of CK20 and Ki67 in representative differentiated organoids from CWH22 and CLM22 (scale bars, 50 μm).

Journal: Aging (Albany NY)

Article Title: A pair of primary colorectal cancer-derived and corresponding synchronous liver metastasis-derived organoid cell lines

doi: 10.18632/aging.205595

Figure Lengend Snippet: CWH22 and CLM22 organoids maintain histological and proliferative characteristics of the corresponding tumors. ( A ) H&E staining of the tumor organoids showing the resemblance of the organoids to the lumens and tubular structures of the primary tumor. IHC staining demonstrated consistent positive expression of CK20 and CDX2 in the organoids and corresponding tumors (scale bars, 100 μm). ( B ) IHC staining of CWH22 and CLM22 organoids demonstrating the consistent expression of p53, Ki67, MLH1, PMS2, MSH2, MSH6, and Villin, with the expression in CRC and CLM tissues . Scale bars, 100 μm. ( C ) Representative time course of CWH22 and CLM22 organoid growth for 14 days (scale bars, 500 μm) and local field amplification (scale bars, 200 μm). ( D ) Analysis of the proliferation rates of CWH22 and CLM22 organoids over time using 3D cell viability tests. ( E ) Bright-field images showing the morphology of CWH22 and CLM22 organoids at the 2nd, 5th, 10th, and 20th passages (P2, P5, P10, and P20, respectively; scale bars, 500 μm), and the expression of CK20 and Ki67 in representative differentiated organoids from CWH22 and CLM22 (scale bars, 50 μm).

Article Snippet: The antibodies used for IHC were as follows: CDX2 (Cat. No. ZA-0520 R), CK20 (Cat. No. ZA-0574 R), MLH1 (Cat. No. ZM-0154), PMS2 (Cat. No. ZA-0542 R), MSH2 (Cat. No. ZA-0622 R), MSH6 (Cat. No. ZA-0541 R), Her-2 (Cat. No. ZA-0641 R), Ki67 (Cat. No. ZM-0166), p53 (Cat. No. ZM-0408), and Villin (Cat. No. ZA-0575 R; all from ZSGB-BIO).

Techniques: Staining, Immunohistochemistry, Expressing, Amplification